CA Patent

CA2673290A1 — Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor

Assigned to Amryt Pharmaceuticals Inc · Expires 2008-07-03 · 18y expired

What this patent protects

The invention is directed to methods for treating and/or controlling obesity in a patient. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, AEGR-733 and implitapide) and a cholesterol absorption inhibitor (CA…

USPTO Abstract

The invention is directed to methods for treating and/or controlling obesity in a patient. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, AEGR-733 and implitapide) and a cholesterol absorption inhibitor (CAI) (for example, ezetimibe).

Drugs covered by this patent

Patent Metadata

Patent number
CA2673290A1
Jurisdiction
CA
Classification
—
Expires
2008-07-03
Drug substance claim
No
Drug product claim
No
Assignee
Amryt Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.